Home › Karsinoma ng Nasopharynx › Georgia
Pag-aaral pangklinika para sa Karsinoma ng Nasopharynx sa Georgia
6 pag-aaral para sa Karsinoma ng Nasopharynx ang naghahanap ng mga kalahok sa mga site sa Georgia.
Mga Lungsod sa Georgia
Opisyal na teksto ng pag-aaral (English)
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- Emory University Hospital Midtown, Atlanta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Emory University Hospital Midtown, Atlanta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Nagre-recruitPhase 2
Hanggang edad 21 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06064097Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT06662058TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 4, 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 11, 2026 · NCT06636734Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.